Sanctura Growth Pushed By Urinary Incontinence Awareness, Pliva Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pliva says the recent addition of three new products to the urinary incontinence market is "positive" because of the increase in awareness of the condition. Sanctura has "almost 8%" of market share among urologists, a figure the company hopes will "trickle down" to general practitioners, Pliva says.
You may also be interested in...
Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
Sanctura Accounts For 7.6% Of New Overactive Bladder Scripts By Urologists
Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.